Literature DB >> 22282494

CMV-specific cellular therapy for acute myeloid leukemia?

Kirsty J Thomson, Stephen Mackinnon, Karl S Peggs.   

Abstract

Entities:  

Mesh:

Year:  2012        PMID: 22282494     DOI: 10.1182/blood-2011-10-383943

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  14 in total

1.  Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.

Authors:  Shivaprasad Manjappa; Pavan Kumar Bhamidipati; Keith E Stokerl-Goldstein; John F DiPersio; Geoffrey L Uy; Peter Westervelt; Jingxia Liu; Mark A Schroeder; Ravi Vij; Camille N Abboud; Todd A Fehniger; Amanda F Cashen; Iskra Pusic; Meagan Jacoby; Srinidhi J Meera; Rizwan Romee
Journal:  Biol Blood Marrow Transplant       Date:  2013-10-10       Impact factor: 5.742

Review 2.  The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.

Authors:  Frank Cichocki; Michael R Verneris; Sarah Cooley; Veronika Bachanova; Claudio G Brunstein; Bruce R Blazar; John Wagner; Heinrich Schlums; Yenan T Bryceson; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

3.  Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant.

Authors:  Jonathan U Peled; Robert R Jenq
Journal:  Leuk Lymphoma       Date:  2016-10-12

4.  Cytomegalovirus induces strong antileukemic effect in acute myeloid leukemia patients following sibling HSCT without ATG-containing regimen.

Authors:  Xiebing Bao; Qian Zhu; Shengli Xue; Xiaohui Hu; Xiao Ma; Feng Chen; Suning Chen; Aining Sun; Depei Wu; Jianhua Yu; Xiaojin Wu; Huiying Qiu
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

5.  CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.

Authors:  Margaret L Green; Wendy M Leisenring; Hu Xie; Roland B Walter; Marco Mielcarek; Brenda M Sandmaier; Stanley R Riddell; Michael Boeckh
Journal:  Blood       Date:  2013-06-06       Impact factor: 22.113

6.  Mechanism of tumor remission by cytomegalovirus in a murine lymphoma model: evidence for involvement of virally induced cellular interleukin-15.

Authors:  Katja C Erlach; Matthias J Reddehase; Jürgen Podlech
Journal:  Med Microbiol Immunol       Date:  2015-03-25       Impact factor: 3.402

7.  Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.

Authors:  Pierre Teira; Minoo Battiwalla; Muthalagu Ramanathan; A John Barrett; Kwang Woo Ahn; Min Chen; Jaime S Green; Ayman Saad; Joseph H Antin; Bipin N Savani; Hillard M Lazarus; Matthew Seftel; Wael Saber; David Marks; Mahmoud Aljurf; Maxim Norkin; John R Wingard; Caroline A Lindemans; Michael Boeckh; Marcie L Riches; Jeffery J Auletta
Journal:  Blood       Date:  2016-02-16       Impact factor: 22.113

8.  CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML.

Authors:  S Ito; P Pophali; Wu CO; E K Koklanaris; J Superata; G A Fahle; R Childs; M Battiwalla; A J Barrett
Journal:  Bone Marrow Transplant       Date:  2013-04-08       Impact factor: 5.483

9.  Impact of early CMV reactivation in cord blood stem cell recipients in the current era.

Authors:  M Ramanathan; P Teira; M Battiwalla; J Barrett; K W Ahn; M Chen; J Green; M Laughlin; H M Lazarus; D Marks; A Saad; M Seftel; W Saber; B Savani; E K Waller; J Wingard; J J Auletta; C A Lindemans; M Boeckh; M L Riches
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

10.  Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.

Authors:  Ryotaro Nakamura; Ketevan Gendzekhadze; Joycelynne Palmer; Ni-Chun Tsai; Sally Mokhtari; Stephen J Forman; John A Zaia; David Senitzer; Guido Marcucci; Anthony Stein
Journal:  Leuk Res       Date:  2019-09-28       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.